MeiraGTx (MGTX) CFO & COO Richard Giroux Sells $557K of Stock
Key Points
- MeiraGTx CFO and COO Richard Giroux sold 56,000 shares of stock on October 20, 2026, at an average price of $9.95 per share under a planned trading arrangement.
- After the trade, Richard Giroux holds 852,530 $MGTX shares, down 6.16% from before the trade.
- Major funds like Perceptive Advisors and Rubric Capital held substantial positions in the clinical-stage genetic medicines company as of mid-2026.
- The biotechnology firm recently reported trailing-twelve-month revenue of $397.5 million with an upcoming earnings report scheduled for November 12, 2026.
Get MeiraGTx Holdings plc text alerts
We text you when insiders, Congress, analysts or big funds move on $MGTX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated MeiraGTx Holdings plc alert may contain errors. Disclosures
MeiraGTx Holdings plc CFO and COO Richard Giroux sold 56,000 shares of the company on October 20, 2026. According to a Form 4 filing with the SEC, the transaction was executed at a price of $9.95 per share for a total value of $557,200.
MGTX
MeiraGTx Holdings plc
Inside Richard Giroux's MeiraGTx Trade
Giroux carried out the sale under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, he directly holds 852,530 shares of the genetic medicines company, which represents a 6.16% decrease in his personal stake. The stock did not have a recorded closing price on the transaction date, but the company's shares recently traded around $9.97.
Other Institutional Activity in MeiraGTx
Large institutional investors have adjusted their positions in the clinical-stage biotech firm over recent quarters. Sanofi held 12,197,737 shares valued at about $121.6 million without changing its position. Perceptive Advisors Llc grew its holdings by 460,545 shares, ending with 10,786,658 shares worth about $107.5 million, a 4.5% increase. Rubric Capital Management LP increased its stake by 2,100,000 shares for a 30.0% boost, finishing with 9,100,000 shares valued at about $90.7 million. Johnson & Johnson maintained its holding of 6,641,064 shares worth about $66.2 million. Adage Capital Partners GP L.L.C. added 400,000 shares, growing its stake 10.0% to 4,400,000 shares worth about $43.9 million.
MeiraGTx Holdings plc Stock Up 5.5%
MeiraGTx shares recently traded around $9.97, sitting below both their 50-day moving average of $12.44 and their 200-day moving average of $10.21. The stock trades down about 35.0% from its 52-week high of $15.35 and up about 50.6% from its 52-week low of $6.62.
Recent Earnings
The company posted trailing-twelve-month revenue of $397.5 million and earnings of $0.87 per share. MeiraGTx has a P/E ratio of 11.46. Its next quarterly financial update is scheduled for November 12, 2026.
Insider Buying and Selling at MeiraGTx Holdings plc
Insiders have been active in the stock throughout the year. CEO Alexandria Forbes acquired 980,000 shares on June 25, 2026. General Counsel Robert Wollin purchased 100,000 shares on June 25, 2026, and Chief Scientific Officer Stuart Naylor bought 70,000 shares on the same day.
Analysts Set New Price Targets
Wall Street firms maintain varied outlooks on the stock. Goldman Sachs initiated coverage with a Neutral rating and a $16 price target on September 24, 2026. Earlier in the summer, RBC Capital and HC Wainwright updated their targets, with RBC raising its target to $27 in August.
About MeiraGTx Holdings plc
MeiraGTx is a New York-based clinical-stage genetic medicines company focused on treatments for serious diseases. The firm develops therapies targeting ocular conditions like inherited retinal diseases, neurodegenerative disorders, and xerostomia.
Bottom Line
Richard Giroux's planned sale reduces his direct ownership in MeiraGTx following earlier insider purchases by top executives. Investors are looking ahead to the company's next earnings report on November 12, 2026, for further updates on its genetic therapy pipeline.
Related Filing Alerts
Source: Richard Giroux's Form 4 filing on $MGTX (Oct 20, 2026). Written by software, not financial advice. How we make alerts